Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1100620220090040296
Clinical and Experimental Emergency Medicine
2022 Volume.9 No. 4 p.296 ~ p.303
Comparison of intracranial pressure changes in out-of-hospital cardiac arrest patients with and without malignant blood-brain barrier disruption
Lee Seung-Woo

You Yeon-Ho
Ahn Hong-Joon
Park Jung-Soo
Jeong Won-Joon
Kang Chang-Shin
Min Jin-Hong
In Yong-Nam
Abstract
Objective: In the present study, intracranial pressure (ICP) changes were investigated in out-ofhospital cardiac arrest (OHCA) patients with and without malignant blood-brain barrier (BBB) disruption who underwent target temperature management.

Methods: This prospective, single-center, observational study was conducted from June 2019 to December 2021. ICP and albumin quotient values were measured on days 1, 2, 3, and 4 of hospitalization. Malignant BBB disruption was defined as the sum of scores for the degree of BBB disruption ¡Ã9 on days 1 to 4.

Results: ICP in OHCA patients without malignant BBB disruption on days 1, 2, 3, and 4 of hospitalization was 9.58¡¾0.53, 12.32¡¾0.65, 14.39¡¾0.76, and 13.88¡¾0.87 mmHg, respectively, and in OHCA patients with malignant BBB disruption 13.65¡¾0.74, 15.72¡¾0.67, 16.10¡¾0.92, and 15.22¡¾0.87 mmHg, respectively (P<0.001, P<0.001, P=0.150, and P=0.280, respectively). The P-values of changes in ICP between days 1 and 2, days 2 and 3, and days 3 and 4 of hospitalization in OHCA patients without malignant BBB disruption were P<0.001, P=0.001, and P=0.540, respectively, and in OHCA patients with malignant BBB disruption were P=0.002, P=0.550, and P=0.100, respectively.

Conclusion: Among OHCA patients treated with target temperature management, ICP was higher on days 1 and 2 of hospitalization and an increase in ICP occurred earlier with malignant BBB disruption than without malignant BBB disruption.
KEYWORD
Intracranial pressure, Out-of-hospital cardiac arrest, Blood-brain barrier, Induced hypothermia
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed